Cargando…

Case Management of COVID-19 (Secondary Version)

Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are lik...

Descripción completa

Detalles Bibliográficos
Autor principal: Kato, Yasuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355701/
https://www.ncbi.nlm.nih.gov/pubmed/34414312
http://dx.doi.org/10.31662/jmaj.2021-0036
_version_ 1783736813193527296
author Kato, Yasuyuki
author_facet Kato, Yasuyuki
author_sort Kato, Yasuyuki
collection PubMed
description Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts. Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups.
format Online
Article
Text
id pubmed-8355701
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Japan Medical Association
record_format MEDLINE/PubMed
spelling pubmed-83557012021-08-18 Case Management of COVID-19 (Secondary Version) Kato, Yasuyuki JMA J Review Article: COVID-19 Case management of COVID-19 is critically important to save lives and reduce the fear and anxiety evoked by this disease in communities. However, most healthcare systems have been overwhelmed in many parts of the world. It is also essential to screen patients to be able to identify those who are likely to suffer from severe disease, to ensure more effective use of medical resources. Disease severity can be determined based on simple vital signs; some laboratory markers are useful adjuncts. Treatment for COVID-19 is largely supportive although a number of repurposed drugs have been evaluated for its efficacy in clinical trials. For example, dexamethasone has now been considered as a standard therapy for severe cases, while remdesivir and tocilizumab are promising agents in selected patient groups. Japan Medical Association 2021-07-09 2021-07-15 /pmc/articles/PMC8355701/ /pubmed/34414312 http://dx.doi.org/10.31662/jmaj.2021-0036 Text en Copyright © Japan Medical Association https://creativecommons.org/licenses/by/4.0/JMA Journal is an Open Access journal distributed under the Creative Commons Attribution 4.0 International License. To view the details of this license, please visit (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ).
spellingShingle Review Article: COVID-19
Kato, Yasuyuki
Case Management of COVID-19 (Secondary Version)
title Case Management of COVID-19 (Secondary Version)
title_full Case Management of COVID-19 (Secondary Version)
title_fullStr Case Management of COVID-19 (Secondary Version)
title_full_unstemmed Case Management of COVID-19 (Secondary Version)
title_short Case Management of COVID-19 (Secondary Version)
title_sort case management of covid-19 (secondary version)
topic Review Article: COVID-19
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355701/
https://www.ncbi.nlm.nih.gov/pubmed/34414312
http://dx.doi.org/10.31662/jmaj.2021-0036
work_keys_str_mv AT katoyasuyuki casemanagementofcovid19secondaryversion